SMi Group's Inaugural Peptides conference
Upcoming SlideShare
Loading in...5
×

Like this? Share it with your network

Share

SMi Group's Inaugural Peptides conference

  • 423 views
Uploaded on

SMi Group has introduced its Peptides conference to the its schedule this June in London

SMi Group has introduced its Peptides conference to the its schedule this June in London

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
No Downloads

Views

Total Views
423
On Slideshare
419
From Embeds
4
Number of Embeds
1

Actions

Shares
Downloads
0
Comments
0
Likes
1

Embeds 4

http://www.slideee.com 4

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. O FO 3 B R R 1 O FO BO £3 ST OK R OK 00 MA B £1 B D R Y 00 Y IS CH DI 30 CO SC TH UN O AP T UN R T IL SMi present their inaugural conference on… 30TH JUNE 1ST JULY PEPTIDES Assessing Analytical Developments, Peptide Formulation and Delivery to Enhance Therapeutic Developments 2014 Marriott Regents Park Hotel, London, UK CHAIRS FOR 2014: Joel Richard, Vice President, Peptides, IPSEN Inc. Yvonne Angell, Director of Peptide and Protein Chemistry, IPSEN Inc. KEY SPEAKERS INCLUDE: • Thomas Vorherr, Director Peptide Discovery, Novartis Pharma AG • Christian Luber, Senior Scientist, Novo Nordisk • Nuno Madeira do O, Associate Scientist II, Formulation Sciences, MedImmune • David Price, Senior Director, Pfizer • Ved Srivastava, Head, Peptide Chemistry, GlaxoSmithKline • Dinesh V. Patel, President and CEO, Protagonist Therapeutics Inc. • Annette Friebe, Head, Late Discovery, Nexigen GmbH • Christophe Bonny, CSO, Bicycle Therapeutics BUSINESS BENEFITS FOR 2014: • Gain insight into engineering peptide therapeutics for optimal drug delivery • Hear what analytical methods can be utilised to enhance product design • Strengthen your knowledge on strategies to enhance the development of novel peptides • Assess new formulations and routes for administration of peptides PLUS AN INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOP Wednesday 2nd July 2014, Marriott Regents Park Hotel, London, UK Extending the Half-Life of Peptides Workshop Leader: Yvonne Angell, Director of Peptide and Protein Chemistry, IPSEN Inc. 8.30am – 12.30pm www.peptidesevent.com BOOK BY 31ST MARCH AND SAVE £300 / BOOK BY 30TH APRIL AND SAVE £100 Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711 @SMIpharm
  • 2. Peptides www.peptide Day One | Monday 30th June 2014 8.30 Registration & Coffee 9.00 Chairman's Opening Remarks Yvonne Angell, Director of Peptide and Protein Chemistry, IPSEN Inc. 1.30 Responsive delivery systems for extended release of peptides and proteins PEPTIDE FORMUALTION AND DELIVERY 9.10 • Strategies for solubilisation and stability enhancement • Tuning release rates • Manufacturing and device selection Fredrik Tiberg, President and CEO, Camurus AB PART ONE OPENING ADDRESS Physical and Conformational Stability: Understanding, Characterising and Formulating Peptides • Introduction • Formulation challenges and characterisation techniques • Case Study • Concluding remarks Nuno Madeira do O, Associate Scientist II, Formulation Sciences, MedImmune SPOTLIGHT PRESENTATION 2.10 Challenges for the design of permeable therapeutic peptides • Peptide synthesis • Intracellular transport • Oral bioavailability Thomas Vorherr, Director Peptide Discovery, Novartis Pharma AG 2.50 9.10 Case study: Development of cell-permeable therapeutic peptides targeting Wnt signalling in cancer • Identification of functional peptides utilizing a cellular yeast screening platform • Development of cell-permeable peptides with anti-tumour activity in vitro and in vivo • Pharmacology of the lead candidate Annette Friebe, Head, Late Discovery, Nexigen GmbH Afternoon Tea 3.20 Novel Hepcidin Agonists • Hepcidin is a natural peptide hormone that regulates iron homeostasis. Hepcidin deficiency is associated with iron overload disorders such as beta-thalassemia and juvenile hemochromatosis. • Hepcidin is structurally complex (25-mer with 4-disulfidecross linked beta-hairpin), difficult to synthesize, and prone 10.30 11.00 Morning Coffee to aggregation. A hepcidin agonist with suitable drug-like THE DEVELOPMENT OF NEW PEPTIDE DRUGS 11.40 12.20 properties is highly desired. KEYNOTE ADDRESS Oral Bioavailability of Peptides • Strategic way to bring new products to market that are more efficient and have higher efficacy • Linking PK and bio-distribution of peptide therapeutics with their pharmacological activity • Future directions David Price, Senior Director, Pfizer • Protagonist has utilized its proprietary VectrixTM technology platform and ‘scaffold hoping’ to identify novel hepcidin agonists with equivalent in vivo potency to hepcidin and superior physiochemical properties. Gregory T. Bourne, Research Fellow, Protagonist Therapeutics Inc. 4.00 peptide sequence • What challenges are being faced for manufacturing products? Strategies to enhance the development of novel peptide drugs • Enhancing high specificity, potency and low toxicity of novel therapeutics • Improving the viability of oral delivery for peptides • Assessing the distinct advantages peptides have over small molecules Yvonne Angell, Director of Peptide and Protein Chemistry, IPSEN Inc. Networking Lunch Manufacturability – Understanding the criteria to form a •Understanding the characterisation of peptides to understand their risk profile, e.g. solubility •Assessing how the product could behave in large scale manufacturing Annette Friebe, Head, Late Discovery, Nexigen GmbH David Price, Director, Pfizer Joel Richard, Vice President, Peptides, IPSEN Inc. 4.40 Chairman’s Closing Remarks and Close of Day One Register online at: www.peptidesevent.com • Alternatively fax yo SPONSORSHIP AND EXHIBITION OPPORTUNITIES SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy. Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your industry. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call: Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk Want to know how you can get involved? Interested in promoting your services to this market? Contact Humaira Kaiser, SMi Marketing on +44 (0) 207 827 6167, or email: hkaiser@smi-online.co.uk
  • 3. esevent.com 8.30 Registration & Coffee 9.00 Day Two | Tuesday 1st July 2014 Chairman's Opening Remarks Joel Richard, Vice President, Peptides, IPSEN Inc. FORMUALTION AND DELIVERY 9.10 BIOPHYSICAL CHARACTERISATION 1.30 Targeting Mitochondria with Cationic Amphipathic Short Peptides • A novel class of water-soluble tetrapeptides (“SS peptides”) was recently reported, with the view to protect cells against PART TWO ROS-mediated oxidative stress. OPENING ADDRESS Peptide Delivery: Where Do We Stand and What Does the Future Hold? • Current technologies and products • Latest developments of water-based ready-to-use SR formulations of peptides • Alternative, non-invasive oral and transdermal formulations • Assessing improvements to the way drugs are administered Joel Richard, Vice President, Peptides, IPSEN Inc. • We have designed a series of fluorescently-labeled short peptides and have evaluated their ability to co-localize with mitochondria. The effect of different dyes on their biological behaviour was investigated. It was found that the size of the fluorescent probe strongly affected the ability of the compound to efficiently co-localize with mitochondria. • Dansylated peptides were selected as models 9.50 Oral Peptide Drugs • Oral peptide drugs can offer excellent advantages to patients, physicians, and payers versus those targets and diseases wherein ‘injectable antibodies’ is the only available targeted therapy option. • Two complimentary approaches will be discussed – engineering core oral stability in peptide scaffolds vs. using specialized formulation/delivery approaches to protect and off-load the drug to the desired site of action. • Protagonist will disclose its progress towards ‘oral peptides for IBD’ on a clinically validated target. Dinesh V. Patel, President and CEO, Protagonist Therapeutics Inc. for the subsequent incorporation of iron-chelating moieties into the backbone sequence to provide a novel class of mitochondria-targeted iron chelators. Vincenzo Abbate, Research Associate, Kings College London 2.10 Analytical Analysis to Quantify Peptides • Utilising mass spectrometry to accurately quantify peptides in biological matrices • Confirming ELISA measurements or even to replace ELISA 10.30 Morning Coffee 11.00 Reviewing peptide engineering for the optimisation of drug like properties Peptide therapy has become a key strategy of innovative drug development. One of the potential barriers to the use of the native peptides in the clinic is their short half-lives. The presentation will emphasize: • Attributes necessary for a commercially successful metabolic peptide • Strategies and tactics for the design and development of peptidase-resistant peptide analogs and • Strategies for half-life extension to increase the duration of effect including formulation tactics for patient friendly peptide delivery. Ved Srivastava, Head, Peptide Chemistry, GSK through mass spec Christian Luber, Senior Scientist, Novo Nordisk 2.50 Afternoon Tea 3.20 Direct Selection of Drug-Like Macrocyclic Peptides from In Vitro Display Libraries Built with Unnatural Amino Acids • High affinity macrocycles are isolated by affinity to targets of interest • Macrocyclic peptides can adopt conformations that promote extensive intramolecular hydrogen bonding 11.40 12.20 Bi-Cyclic Peptides to Target Protein-Protein Interactions • The Bicycle technology is based on repertoires of peptides displayed on the surface of bacteriophages which can be modified with organochemical scaffolds to create a diverse array of constrained peptides. • These repertoires have been extensively used for iterative selections to identify high affinity binding peptides for a wide array of targets, including receptors, interleukins and proteases. • Results will be presented that exemplify the potential of the technology and its application to animal models of diseases. Christophe Bonny, CSO, Bicycle Therapeutics Networking Lunch • Cell permeability is apparent with certain molecules Doug Treco, President and CEO, Ra Pharma 4.00 Case Study: Advances with Linaclotide • Reserved Speaking Slot Mark Currie, President & CEO, Ironwood Pharmaceuticals* 4.40 Chairman’s Closing Remarks and Close of Day Two *Subject to Final Confirmation our registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711 Supported by
  • 4. HALF-DAY POST-CONFERENCE WORKSHOP Wednesday 2nd July 2014 8.30am – 12.30pm Marriott Regents Park Hotel, London, UK Extending the Half-Life of Peptides Workshop Leader: Yvonne Angell, Director of Peptide and Protein Chemistry, IPSEN Inc. Overview of workshop: The major question to be asked is, can chemical modification technologies (like PEGylation, PASylation, hSA conjugation or even other potential fusion technologies) be able to compete with sustained-release (SR) formulations which now can deliver peptides over up to 6-12 months after administration? What would be the key advantages of peptide conjugation vs SR formulations for half-life extension? Are there specific situations where conjugation brings something that SR formulation cannot achieve? It may include PK assessment of peptides, comparison of PK profile for various systems (conjugated peptides, microsphere/ implant-based systems, self-assembled peptide formulations) and in silico potential tools such as in vitro/in vivo correlations (IVIVC). Agenda: 8.30 Registration and Coffee 9.00 Introdcution from Workshop Host 9.10 Simulation Exercise: Assessing conjugation vs. SR formulation 10.30 Coffee Break 11.00 PK Assessment of Peptides 11.30 Comparing the PK Profile of various systems 12.00 Open Discussion 12.30 End of Workshop About the workshop host: Yvonne M. Angell, Ph.D. Yvonne earned her B.S. in Pharmacy and Ph.D. in Medicinal Chemistry degrees at the University of WisconsinMadison, U.S.A. She completed her post-doctoral work at the University of Minnesota, U.S.A. Yvonne has over 15 years experience in the pharmaceutical industry. Past experience includes designing novel, constrained peptide libraries to inhibit protein-protein interactions as a scientist at Eli Lilly and Co., design and development of bead-based binding assays to identify new hits aimed at inhibiting proteinprotein interactions at Genetics Institute (acquired by Wyeth in 1996, then purchased by Pfizer in 2009), and PEGylation process development optimization of Omontys (peginesatide), which received FDA approval in 2012, as a senior scientist at Affymax. Her current work as Director of Chemistry at Ipsen is focused on discovery, design and engineering of novel, potent, selective lead peptide and peptide chimeric compounds for oncology, endocrinology and neurology targets. She leads project teams as well as a synthetic chemistry group, and has successfully navigated projects from discovery to development.
  • 5. SMI'S PHARMACEUTICAL PORTFOLIO 2014 MARCH Controlled Release 12 – 13 March 2014, London Adaptive Designs 24 – 25 March 2014, London Paediatric Clinical Trials 31 – 1 April 2014, London Pre-Filled Syringes USA 31 March – 1 April 2014, USA APRIL Asthma & COPD 2 – 3 April 2014, London Biosimilars USA 7 – 8 April 2014, USA MAY Big Data in Pharma 12 – 13 May 2014, London Pain Therapeutics 19 – 20 May 2014, London ADC Summit 19 – 20 May 2014, London Clinical Trial Logistics 21 – 22 May 2014, London JUNE Biobanking 23 – 24 June 2014, London ADMET 30 June – 1 July 2014, London Peptides 30 June – 1 July 2014, London JULY Lyophilisation 7 – 8 July 2014, London BioNetworks 7 – 8 July 2014, London Allergies 9 – 10 July 2014, London Immunogenicity 14 – 15 July 2014, London SPONSORSHIP AND EXHIBITION OPPORTUNITIES SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy. Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your industry. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call: Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk
  • 6. PEPTIDES Conference: Monday 30th June and Tuesday 1st July 2014, Marriott Regents Park Hotel, London, UK Workshop: Wednesday 2nd July 2014, London 4 WAYS TO REGISTER www.peptidesevent.com FAX your booking form to +44 (0) 870 9090 712 PHONE on +44 (0) 870 9090 711 POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK EARLY BIRD □ DISCOUNT □ Book by 31st March to receive £300 off the conference price Book by 30th April to receive £100 off the conference price CONFERENCE PRICES Unique Reference Number I would like to attend: (Please tick as appropriate) Fee Total □ Conference & Workshop £2098.00 + VAT £2517.60 DELEGATE DETAILS □ Conference only £1499.00 + VAT £1798.80 Please complete fully and clearly in capital letters. Please photocopy for additional delegates. □ Workshop only £599.00 + VAT £718.80 £999.00 + VAT £1198.80 Our Reference Title: LVP-107 Forename: Surname: PROMOTIONAL LITERATURE DISTRIBUTION Job Title: □ Distribution of your company’s promotional Department/Division: literature to all conference attendees Company/Organisation: Email: The conference fee includes refreshments, lunch, conference papers and access Company VAT Number: to the Document Portal containing all of the presentations. Address: LIVE STREAMING/ON DEMAND/ DOCUMENTATION Town/City: Post/Zip Code: Country: Direct Tel: Direct Fax: Unable to travel, but would like to watch the conference live, ask questions, participate as if you were in the room. Price Total □ Live Streaming □ On demand Mobile: Switchboard: £999.00 + VAT (UK) £1198.80 £599.00 + VAT (UK) £718.80 (available 24 hours after the event) Signature: Date: I agree to be bound by SMi's Terms and Conditions of Booking. on the Document Portal £499.00 + VAT £499.00 (or only £300 if ordered with the Document Portal) ACCOUNTS DEPT Title: □ Access to the conference documentation □ The Conference Presentations - paper copy Forename: Surname: Email: £598.80 £499.00 PAYMENT Address (if different from above): Payment must be made to SMi Group Ltd, and received before the event, by one of the following methods quoting reference P-107 and the delegate’s name. Bookings made within 7 days of the event require payment on booking, methods of payment are below. Please indicate method of payment: Town/City: Post/Zip Code: Country: Direct Tel: Direct Fax: VENUE Marriott Hotel Regents Park, 128 King Henry's Road, London, NW3 3ST □ Please contact me to book my hotel Alternatively call us on +44 (0) 870 9090 711, email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712 Terms and Conditions of Booking Payment: If payment is not made at the time of booking, then an invoice will be issued and must be paid immediately and prior to the start of the event. If payment has not been received then credit card details will be requested and payment taken before entry to the event. Bookings within 7 days of event require payment on booking. Access to the Document Portal will not be given until payment has been received. Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. Two or more delegates may not ‘share’ a place at an event. Please make separate bookings for each delegate. Cancellation: If you wish to cancel your attendance at an event and you are unable to send a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing that cancellation is made in writing and received at least 28 days prior to the start of the event. Regretfully cancellation after this time cannot be accepted. We will however provide the conferences documentation via the Document Portal to any delegate who has paid but is unable to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to provide documentation in these circumstances. We cannot accept cancellations of orders placed for Documentation or the Document Portal as these are reproduced specifically to order. If we have to cancel the event for any reason, then we will make a full refund immediately, but disclaim any further liability. Alterations: It may become necessary for us to make alterations to the content, speakers, timing, venue or date of the event compared to the advertised programme. Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other products and services. Unless you tick here □ we may also share your data with third parties offering complementary products or services. If you have any queries or want to update any of the data that we hold then please contact our Database Manager databasemanager@smi-online.co.uk or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your address on the attached letter. □ UK BACS □ Wire Transfer □ Cheque □ Credit Card Sort Code 300009, Account 00936418 Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU Swift (BIC): LOYDGB21013, Account 00936418 IBAN GB48 LOYD 3000 0900 9364 18 We can only accept Sterling cheques drawn on a UK bank. □ Visa □ MasterCard □ American Express All credit card payments will be subject to standard credit card charges. □□□□ □□□□ □□□□ □□□□ Valid From □□/□□ Expiry Date □□/□□ CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card Card No: Cardholder’s Name: Signature: Date: I agree to be bound by SMi's Terms and Conditions of Booking. Card Billing Address (If different from above): VAT VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on live Streaming, on Demand, Document portal and literature distribution for all UK customers and for those EU Customers not supplying a registration number for their own country here. ______________________________________________________________________________________________ If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email events@smi-online.co.uk